OncLive - "Dr. Montal On Molecular Predictors Of Recurrence With Adjuvant Sorafenib In HCC" - Robert Montal, MD

New York, NY
 – September 17, 2017  –– 

Robert Montal, MD, medical oncology and researcher at the Mount Sinai Liver Cancer Program in the division of liver diseases at the Icahn School of Medicine at Mount Sinai, discussed biomarker findings of the phase III STORM trial, which explored adjuvant treatment with sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC). The results did not identify biomarkers predicting recurrence prevention to sorafenib. Biomarkers related to angiogenesis, proliferation, previously proposed gene signatures or mutations were not independently associated with recurrence or prevention with sorafenib, Dr. Montal adds. However, a multi-gene signature did correlate with an improvement in RFS.

- Robert Montal, MD, Medical Oncologist, Researcher, Mount Sinai Liver Cancer Program, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai

Learn more